Sensitive LC–MS/MS Method for Simultaneous Quantification of Alectinib and Its Major Metabolite M4 in Limited‐Volume Human Plasma
Biomedical Chromatography · 2026-12 · 40 (12)
DOI: 10.1002/bmc.70658 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, online erschienen am 08.11.2026. Verfasst von Reiko Ando Makihara und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Piperidines, Carbazoles, Tandem Mass Spectrometry, Liquid Chromatography-Mass Spectrometry. Die Arbeit nennt 21 Literaturangaben. Gefördert von: Chugai Pharmaceutical Co., Ltd., Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Alectinib is an oral anaplastic lymphoma kinase inhibitor, and M4 is its major pharmacologically active metabolite. Simultaneous quantification of alectinib and M4 in limited‐volume plasma is important for pediatric clinical studies, particularly when concentrations are low or exceed the calibration range. An LC–MS/MS method was developed and validated for simultaneous quantification of alectinib and its major metabolite, M4, in human plasma. Alectinib and M4 were extracted from 20 μL of plasma by protein precipitation and quantified using stable isotope‐labeled internal standards. Calibration ranges were 0.100–20.0 ng/mL for alectinib and 1.00–200 ng/mL for M4, with lower limits of quantification of 0.100 and 1.00 ng/mL, respectively. Full validation demonstrated acceptable selectivity, linearity, matrix effects, dilution reproducibility, stability, and carryover. Inter‐day accuracy (RE) ranged from −9.9% to 5.1%, and inter‐day precision (CV) was ≤ 8.3% for both analytes. Partial validation after analytical column replacement also met predefined acceptance criteria. The method was successfully applied to plasma samples obtained from one patient enrolled in an investigator‐initiated clinical trial of alectinib, with both alectinib and M4 remaining quantifiable up to 72 h after a single oral dose. This sensitive LC–MS/MS method supports the simultaneous quantification of alectinib and M4 in limited‐volume pediatric clinical study samples.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, National Cancer Center Hospital, Tokyo, Japan.
- Department of Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan.
- Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
- Clinical Research Support Office, National Cancer Center Hospital, Tokyo, Japan.
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
ORCID-Profile: Reiko Ando Makihara, Ayumu Arakawa, Yasushi Goto, Yoshimasa Saito
Förderung
- Chugai Pharmaceutical Co., Ltd.
- Japan Agency for Medical Research and Development
Zitieren
APA
Makihara, R. A., Maeda, M., Arakawa, A., Okuma, H. S., Goto, Y., Saito, Y., & Hashimoto, H. (2026). Sensitive LC–MS/MS Method for Simultaneous Quantification of Alectinib and Its Major Metabolite M4 in Limited‐Volume Human Plasma. Biomedical Chromatography, 40(12). https://doi.org/10.1002/bmc.70658
Vancouver
Makihara RA, Maeda M, Arakawa A, Okuma HS, Goto Y, Saito Y, et al. Sensitive LC–MS/MS Method for Simultaneous Quantification of Alectinib and Its Major Metabolite M4 in Limited‐Volume Human Plasma. Biomedical Chromatography. 2026;40(12). doi:10.1002/bmc.70658
BibTeX
@article{Makihara2026,
author = {Makihara, Reiko Ando and Maeda, Makoto and Arakawa, Ayumu and Okuma, Hitomi S and Goto, Yasushi and Saito, Yoshimasa and Hashimoto, Hironobu},
title = {Sensitive LC–MS/MS Method for Simultaneous Quantification of Alectinib and Its Major Metabolite M4 in Limited‐Volume Human Plasma},
journal = {Biomedical Chromatography},
year = {2026},
volume = {40},
number = {12},
doi = {10.1002/bmc.70658}
}
EUVIMED